Log in
Progestogen

Progesterone

Progesterone is a naturally occurring steroid hormone and the prototypical progestogen, essential for preparing the endometrium for implantation and maintaining early pregnancy. It is used clinically for hormone replacement therapy, luteal phase support in assisted reproduction, contraception, and prevention of preterm birth. The most testable fact is its role in converting proliferative endometrium to secretory phase via progesterone receptor activation.

Practice questionsHigh-yield facts
Drug classNaturally occurring progestogen (steroid hormone)
MechanismProgesterone receptor agonist; transforms endometrium, suppresses ovulation
Main usesHRT, luteal support, contraception, preterm birth prevention
Key adverse effectSedation, mood changes, breakthrough bleeding
6 min readFor medical studentsUpdated 2026-10-14

Mechanism of action

Progesterone is a C21 steroid hormone that acts as an agonist at nuclear progesterone receptors (PR-A and PR-B), which are members of the steroid hormone receptor superfamily. Upon binding, the receptor-ligand complex translocates to the nucleus, dimerizes, and binds to progesterone response elements on DNA, modulating transcription of target genes.

Key physiological effects

  • Endometrial transformation: Converts estrogen-primed proliferative endometrium to secretory phase, inducing glandular differentiation and decidualization necessary for embryo implantation
  • Ovulation suppression: At sufficient doses, inhibits the LH surge by negative feedback on the hypothalamic-pituitary-ovarian axis
  • Cervical mucus thickening: Increases viscosity, creating a barrier to sperm penetration
  • Myometrial relaxation: Decreases uterine contractility and reduces sensitivity to oxytocin during pregnancy
  • Breast development: Promotes lobuloalveolar differentiation in mammary tissue
  • CNS effects: Metabolites (allopregnanolone) act as positive allosteric modulators of GABA-A receptors, producing sedative and anxiolytic effects

Progesterone also exhibits weak antimineralocorticoid activity by competing with aldosterone at mineralocorticoid receptors, which can cause mild natriuresis.

High-yield for exams
  • Progesterone transforms estrogen-primed proliferative endometrium into secretory phase, essential for implantation
  • Metabolized to allopregnanolone, a GABA-A receptor positive allosteric modulator causing sedation
  • Progestogen must be added to estrogen HRT in women with intact uterus to prevent endometrial hyperplasia/cancer
  • Oral micronized progesterone has low bioavailability (10%) due to extensive first-pass metabolism
  • Vaginal progesterone exhibits 'first uterine pass effect' with preferential endometrial uptake and lower systemic exposure
  • Progesterone challenge test: withdrawal bleeding after progesterone confirms adequate estrogen and patent outflow tract
  • Natural progesterone has lower thrombotic and cardiovascular risk compared to synthetic progestogens like medroxyprogesterone acetate
  • Vaginal progesterone reduces preterm birth in women with short cervix; 17-OHPC was withdrawn by FDA in 2023

Indications

Hormone replacement therapy: Used in postmenopausal women receiving estrogen replacement to oppose estrogen-induced endometrial hyperplasia and reduce endometrial cancer risk. Progestogen administration for at least 12-14 days per cycle is standard for women with an intact uterus.

Luteal phase support: In assisted reproductive technology (IVF, ICSI), progesterone supplementation supports the endometrium after ovarian stimulation and egg retrieval, compensating for corpus luteum insufficiency.

Secondary amenorrhea: Diagnostic and therapeutic tool to induce withdrawal bleeding in women with anovulation and intact estrogen production, differentiating hypothalamic-pituitary from uterine causes.

Abnormal uterine bleeding: Cyclical or continuous progestogen therapy can regulate menstrual cycles in anovulatory dysfunctional uterine bleeding once structural pathology is excluded.

Prevention of preterm birth: Vaginal micronized progesterone is used in women with a short cervix (<25 mm) detected on mid-trimester ultrasound to reduce preterm birth risk. Note that 17-hydroxyprogesterone caproate (17-OHPC) is no longer recommended or available, as the FDA withdrew approval in 2023 after the PROLONG trial demonstrated lack of efficacy for preventing recurrent preterm birth.

Contraception: Combined with estrogen in oral contraceptives, or alone in progestin-only pills, implants, injections, and intrauterine systems.

Endometriosis and endometrial hyperplasia: Progestogenic effects suppress endometrial proliferation and ectopic endometrial tissue.

Pharmacokinetics

Absorption: Oral bioavailability is low (10%) due to extensive first-pass hepatic metabolism. Micronized formulations improve absorption. Intramuscular and vaginal routes bypass first-pass metabolism and provide more consistent serum levels.

Distribution: Highly lipophilic; approximately 96-99% protein-bound, primarily to albumin and corticosteroid-binding globulin. Widely distributed to tissues including the CNS.

Metabolism: Extensively metabolized in the liver by reduction and conjugation. Major metabolites include pregnanediol and allopregnanolone. Allopregnanolone contributes to sedative effects via GABA-A receptor modulation.

Excretion: Metabolites are excreted primarily in urine as glucuronide and sulfate conjugates. Elimination half-life is approximately 5-20 minutes for intravenous progesterone, but sustained-release formulations extend duration of action.

Route-specific considerations: Vaginal administration results in preferential uterine uptake ("first uterine pass effect") with lower systemic exposure compared to oral or intramuscular routes, which is advantageous for endometrial effects with fewer systemic side effects.

Adverse effects

Common

  • CNS effects: Sedation, dizziness, fatigue, headache (related to allopregnanolone and GABAergic activity)
  • Gastrointestinal: Nausea, bloating, abdominal cramping
  • Menstrual irregularities: Breakthrough bleeding, spotting, amenorrhea (dose-dependent)
  • Breast tenderness: Mastodynia
  • Mood changes: Depression, irritability, anxiety
  • Injection site reactions: Pain, swelling, sterile abscess (with intramuscular administration)

Serious

  • Thromboembolic events: Increased risk of venous thromboembolism, particularly with synthetic progestogens and when combined with estrogen; natural progesterone appears to have lower thrombotic risk
  • Cardiovascular: Possible increased risk of stroke and myocardial infarction in postmenopausal women, especially with oral synthetic progestogens
  • Hypersensitivity reactions: Rare anaphylaxis, urticaria, angioedema
  • Hepatotoxicity: Cholestatic jaundice (rare)

Other considerations

Pregnancy category: Progesterone is FDA pregnancy category B (no evidence of risk). It is used therapeutically during pregnancy for preterm birth prevention and luteal support.

Breastfeeding: Compatible with breastfeeding; small amounts enter breast milk but are not expected to harm the infant. May slightly reduce milk volume at high doses.

Contraindications and warnings

Absolute contraindications

  • Known or suspected breast cancer or other progesterone-sensitive malignancy (current or history)
  • Active or history of thromboembolic disorder (DVT, PE, cerebrovascular accident)
  • Active liver disease or hepatic dysfunction
  • Undiagnosed abnormal vaginal bleeding
  • Known hypersensitivity to progesterone or formulation excipients
  • Missed abortion or ectopic pregnancy (in context of luteal support)

Warnings and precautions

Cardiovascular disease: Use with caution in women with risk factors for arterial or venous thrombosis. Natural progesterone may have a more favorable cardiovascular profile than synthetic progestogens.

Depression: Can exacerbate pre-existing depression or mood disorders; monitor closely.

Fluid retention: May cause edema; use with caution in conditions aggravated by fluid retention (cardiac or renal dysfunction, epilepsy, migraine).

Glucose metabolism: May affect glucose tolerance; monitor diabetic patients.

Breakthrough bleeding: Persistent irregular bleeding warrants investigation to exclude endometrial pathology or malignancy.

Peanut allergy: Some formulations contain peanut oil; avoid in patients with peanut or soy allergy.

Driving and operating machinery: Sedation and dizziness may impair ability to perform tasks requiring alertness, particularly with oral micronized formulations.

Drug interactions

CYP450 interactions

Progesterone is metabolized primarily by CYP3A4, CYP2C19, and 5α-reductase enzymes.

CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, phenobarbital, St. John's wort): Increase progesterone metabolism, reducing efficacy. May compromise contraceptive effectiveness and require dose adjustment or alternative contraception.

CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin, grapefruit juice): May increase progesterone levels and adverse effects, though clinically significant interactions are uncommon with natural progesterone.

Hormonal interactions

Estrogens: Progesterone is commonly co-administered with estrogen in HRT and contraception. The combination reduces endometrial hyperplasia risk but may increase thromboembolic risk compared to estrogen alone.

Bromocriptine: Progesterone may interfere with the efficacy of bromocriptine in treating hyperprolactinemia.

Other interactions

Cyclosporine: Progesterone may increase cyclosporine levels by inhibiting its metabolism; monitor cyclosporine concentrations.

Benzodiazepines and CNS depressants: Additive sedative effects due to shared GABAergic activity; use caution with concurrent administration.

Anticoagulants: Monitor anticoagulation parameters, as hormonal therapies may alter coagulation factor synthesis.

Clinical pearls

  • Progesterone challenge test: Administration of oral progesterone (10 mg daily for 5-10 days) followed by withdrawal bleeding confirms an estrogen-primed endometrium and patent outflow tract, helping diagnose anovulatory amenorrhea versus hypothalamic/pituitary dysfunction.
  • Route matters for side effects: Oral micronized progesterone causes more sedation and dizziness due to first-pass hepatic conversion to allopregnanolone. Vaginal administration provides good endometrial effects with fewer CNS side effects.
  • Natural vs. synthetic progestogens: Natural progesterone (micronized progesterone, identical to endogenous hormone) has a more favorable safety profile, particularly regarding cardiovascular and breast cancer risk, compared to synthetic progestogens (medroxyprogesterone acetate, norethisterone).
  • Timing of HRT administration: In sequential HRT regimens, progestogen is added for at least 12-14 days per cycle to ensure adequate endometrial shedding and minimize hyperplasia risk.
  • Preterm birth prevention: Vaginal progesterone is effective for women with short cervix (<25 mm) on mid-trimester ultrasound. Note that 17-hydroxyprogesterone caproate is no longer recommended following FDA withdrawal in 2023 due to lack of demonstrated efficacy.
  • Injection technique: Intramuscular progesterone in oil should be administered deep IM, preferably in the gluteal muscle, and the injection site should be rotated to minimize reactions.
  • Breakthrough bleeding management: In contraceptive or HRT use, breakthrough bleeding typically improves after 3 months. Persistent bleeding requires investigation, including endometrial biopsy to exclude pathology.
  • Exam associations: Progesterone is the hormone measured in the luteal phase to confirm ovulation (>3 ng/mL indicates ovulation occurred). It is also the key hormone maintaining early pregnancy until placental steroidogenesis takes over around week 10.
Mnemonic

PREP for progesterone effects: Prepares endometrium for implantation, Relaxes myometrium, Elevates basal body temperature, Proliferation opposed (anti-estrogenic on endometrium)

Practice questions

1. A 32-year-old woman undergoing IVF receives vaginal progesterone supplementation starting the day after oocyte retrieval. She tolerates the medication well but asks why vaginal rather than oral administration was chosen. Which of the following best explains the advantage of vaginal progesterone for luteal phase support?

Answer: B. Vaginal progesterone demonstrates a 'first uterine pass effect' with preferential distribution to the uterus, achieving high endometrial concentrations while minimizing systemic exposure and side effects like sedation and dizziness. This route bypasses first-pass hepatic metabolism and provides consistent levels ideal for endometrial support. Higher systemic bioavailability (option A) is not the goal; local uterine effects are desired. While reduced hepatic metabolism occurs, drug interactions are not the primary concern for this indication.

2. A 28-year-old woman with secondary amenorrhea undergoes a progesterone withdrawal test. After 10 days of oral micronized progesterone 200 mg daily, she experiences withdrawal bleeding 3 days after completing the course. Which of the following conclusions can be drawn from this result?

Answer: A. A positive progesterone withdrawal test (withdrawal bleeding after progesterone administration) confirms that the endometrium is responsive to progesterone, which requires prior estrogen priming, and that the outflow tract is patent. This indicates the patient is producing adequate estrogen but is anovulatory. It does not confirm normal hypothalamic-pituitary function (option D), as the patient is not ovulating spontaneously. It also does not diagnose the specific cause of anovulation such as PCOS, though PCOS is a common etiology.

3. A 55-year-old postmenopausal woman taking oral estradiol for hot flashes is started on micronized progesterone 200 mg at bedtime. She reports significant drowsiness in the morning that interferes with work. Which pharmacological mechanism best explains her sedation?

Answer: C. Oral micronized progesterone undergoes extensive first-pass hepatic metabolism to allopregnanolone, a neurosteroid that acts as a positive allosteric modulator of GABA-A receptors, producing sedative, anxiolytic, and hypnotic effects similar to benzodiazepines. This explains the drowsiness and is why oral progesterone is often taken at bedtime. Switching to vaginal administration reduces this side effect by bypassing first-pass metabolism. Direct progesterone receptor effects in the brain do not primarily mediate sedation, and antimineralocorticoid effects are weak and would not cause significant sedation.

Frequently asked questions

How does progesterone work?

Progesterone binds to nuclear progesterone receptors, forming a complex that regulates gene transcription to transform the endometrium into secretory phase, suppress ovulation, thicken cervical mucus, and relax the myometrium. Its metabolite allopregnanollone acts on GABA-A receptors in the brain, producing sedative effects. These actions prepare the uterus for pregnancy and maintain early gestation.

What are the side effects of progesterone?

Common side effects include sedation, dizziness, fatigue, headache, nausea, bloating, breast tenderness, mood changes, and breakthrough bleeding. Serious but rare effects include venous thromboembolism, particularly when combined with estrogen. Intramuscular injections can cause local pain and injection site reactions. Oral formulations tend to cause more sedation due to first-pass metabolism to allopregnanolone.

Is progesterone safe during pregnancy?

Yes, progesterone is FDA pregnancy category B and is naturally produced during pregnancy to maintain gestation. It is used therapeutically for luteal phase support in IVF and prevention of preterm birth with vaginal progesterone in women with short cervix. Natural progesterone does not cause birth defects, though synthetic progestogens historically used in early pregnancy raised concerns about virilization. Note that 17-hydroxyprogesterone caproate is no longer available after FDA withdrawal in 2023.

What is the difference between progesterone and progestin?

Progesterone is the naturally occurring hormone (P4) produced by the corpus luteum and placenta. Progestin is a broader term encompassing progesterone and synthetic compounds with progesterone-like activity (medroxyprogesterone acetate, norethisterone, levonorgestrel). Synthetic progestins often have different receptor affinities, longer half-lives, and may exhibit androgenic, antiandrogenic, or glucocorticoid effects. Natural progesterone generally has a more favorable safety profile, especially regarding cardiovascular and breast cancer risk.

Why is progesterone given with estrogen in HRT?

Progesterone is added to estrogen HRT in women with an intact uterus to oppose estrogen's proliferative effects on the endometrium. Unopposed estrogen increases the risk of endometrial hyperplasia and cancer up to 10-fold. Adding progestogen for at least 12-14 days per cycle or continuously transforms the endometrium, induces shedding, and reduces endometrial cancer risk to levels similar to or below untreated women.

Conditions it is used for

secondary amenorrheaabnormal uterine bleedingendometrial hyperplasialuteal phase deficiencypreterm birth (prevention)menopausal symptomsendometriosisinfertility
medroxyprogesterone acetatenorethisteronelevonorgestreldrospirenoneetonogestrelestradiol17-hydroxyprogesterone caproatedienogest

Sources and further reading

DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: G03DA04

Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.